An updated pharmacological insight of resveratrol in the treatment of diabetic nephropathy
- PMID: 33631244
- DOI: 10.1016/j.gene.2021.145532
An updated pharmacological insight of resveratrol in the treatment of diabetic nephropathy
Abstract
As one of the most common complications of diabetes, nephropathy develops in approximately 40% of diabetic individuals. Although end stage kidney disease is known as one of the most consequences of diabetic nephropathy, the majority of diabetic individuals might die from cardiovascular diseases and infections before renal replacement treatment. Moreover, the routine medical treatments for diabetes hold undesirable side effects. The explosive prevalence of diabetes urges clinicians and scientists to investigate the complementary or alternative therapies. Phytochemicals are emerging as alternatives with a wide range of therapeutic effects on various pathologies, including diabetic kidney disease. Of those phytochemicals, resveratrol, a natural polyphenolic stilbene, has been found to exert a broad spectrum of health benefits via various signaling molecules. In particular, resveratrol has gained a great deal of attention because of its anti-oxidative, anti-inflammatory, anti-diabetic, anti-obesity, cardiovascular-protective, and anti-tumor properties. In the renal system, emerging evidence shows that resveratrol has already been used to ameliorate chronic or acute kidney injury. This review critically summarizes the current findings and molecular mechanisms of resveratrol in diabetic renal damage. In addition, we will discuss the adverse and inconsistent effects of resveratrol in diabetic nephropathy. Although there is increasing evidence that resveratrol affords great potential in diabetic nephropathy therapy, these results should be treated with caution before its clinical translation. In addition, the unfavorable pharmacokinetics and/or pharmacodynamics profiles, such as poor bioavailability, may limit its extensive clinical applications. It is clear that further research is needed to unravel these limitations and improve its efficacy against diabetic nephropathy. Increasing investigation of resveratrol in diabetic kidney disease will not only help us better understand its pharmacological actions, but also provide novel potential targets for therapeutic intervention.
Keywords: Diabetes; Nephropathy; Oxidative stress; Phytochemicals; Resveratrol.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Therapeutic Potential of Resveratrol in Diabetic Nephropathy According to Molecular Signaling.Curr Mol Pharmacol. 2022;15(5):716-735. doi: 10.2174/1874467215666211217122523. Curr Mol Pharmacol. 2022. PMID: 34923951 Review.
-
Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.Cardiovasc Ther. 2012 Feb;30(1):49-59. doi: 10.1111/j.1755-5922.2010.00218.x. Epub 2010 Aug 16. Cardiovasc Ther. 2012. PMID: 20718759 Review.
-
A novel compound AB38b attenuates oxidative stress and ECM protein accumulation in kidneys of diabetic mice through modulation of Keap1/Nrf2 signaling.Acta Pharmacol Sin. 2020 Mar;41(3):358-372. doi: 10.1038/s41401-019-0297-6. Epub 2019 Oct 23. Acta Pharmacol Sin. 2020. PMID: 31645661 Free PMC article.
-
Metabolic memory and diabetic nephropathy: Beneficial effects of natural epigenetic modifiers.Biochimie. 2020 Mar;170:140-151. doi: 10.1016/j.biochi.2020.01.007. Epub 2020 Jan 16. Biochimie. 2020. PMID: 31954720 Review.
-
Resveratrol - A comprehensive review of recent advances in anticancer drug design and development.Eur J Med Chem. 2020 Aug 15;200:112356. doi: 10.1016/j.ejmech.2020.112356. Epub 2020 May 19. Eur J Med Chem. 2020. PMID: 32485531 Review.
Cited by
-
Bone-kidney axis: A potential therapeutic target for diabetic nephropathy.Front Endocrinol (Lausanne). 2022 Oct 24;13:996776. doi: 10.3389/fendo.2022.996776. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36353239 Free PMC article. Review.
-
Construction of a Prediction Model for the Mortality of Elderly Patients with Diabetic Nephropathy.J Healthc Eng. 2022 Sep 12;2022:5724050. doi: 10.1155/2022/5724050. eCollection 2022. J Healthc Eng. 2022. PMID: 36133909 Free PMC article.
-
Association of different obesity indexes with diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study.Sci Rep. 2024 Sep 16;14(1):21571. doi: 10.1038/s41598-024-73106-3. Sci Rep. 2024. PMID: 39284924 Free PMC article.
-
Multiple roles of mitochondrial autophagy receptor FUNDC1 in mitochondrial events and kidney disease.Front Cell Dev Biol. 2024 Oct 9;12:1453365. doi: 10.3389/fcell.2024.1453365. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39445333 Free PMC article. Review.
-
Resveratrol delays the progression of diabetic nephropathy through multiple pathways: A dose-response meta-analysis based on animal models.J Diabetes. 2024 Sep;16(9):e13608. doi: 10.1111/1753-0407.13608. J Diabetes. 2024. PMID: 39264004 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials